[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

AR022085A1 - Una forma de dosificacion farmaceutica de liberacion sostenida y una tableta comprimida - Google Patents

Una forma de dosificacion farmaceutica de liberacion sostenida y una tableta comprimida

Info

Publication number
AR022085A1
AR022085A1 ARP990104545A ARP990104545A AR022085A1 AR 022085 A1 AR022085 A1 AR 022085A1 AR P990104545 A ARP990104545 A AR P990104545A AR P990104545 A ARP990104545 A AR P990104545A AR 022085 A1 AR022085 A1 AR 022085A1
Authority
AR
Argentina
Prior art keywords
ranolazine
sustained
dosage form
pharmaceutical dosage
compressed tablet
Prior art date
Application number
ARP990104545A
Other languages
English (en)
Original Assignee
Roche Palo Alto Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26796494&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR022085(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Palo Alto Llc filed Critical Roche Palo Alto Llc
Publication of AR022085A1 publication Critical patent/AR022085A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

Uso de una forma de dosificacion farmacéutica de liberacion sostenida, que es para la manufactura de un medicamento que incluye por lo menos 50% en peso deranolazina en no más de dos tabletas por dosis, para mantener niveles de plasma de ranolazinae n el paciente humano de desde aproximadamente 550 aaproximadamente 7.500 ng base/ml durante por lo menos 24 horas, en donde la dosis se administra a una frecuencia seleccionada entre una, dos y tres vecesdurante 24 horas, para el tratamiento de unpa ciente humano que sufre de una enfermedad cardiovascular seleccionada entre arritmias, angina variante e inducidapor ejercicio e infartacion del miocardio. Una formulacion de ranolazina de liberacion sostenida contiene una mezcla íntima deranolazina y un aglutinantedependiente del pH parcialmente neutralizado, para formar una película que es en su mayoría insoluble en medio acuoso por debajo de pH 4,5 y soluble en medioacuoso superior a pH 4,5. La formulacion es adecuada para laadministracion dos veces al día de ranolazina, y es util para el control del índice de disolucionde ranolazina, y para mantener los niveles de ranolazina de plasma humano a entre 550 y 7.500 ng base/ml. También se describe una tableta comprimida.
ARP990104545A 1998-09-10 1999-09-09 Una forma de dosificacion farmaceutica de liberacion sostenida y una tableta comprimida AR022085A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9980498P 1998-09-10 1998-09-10
US09/321,522 US6303607B1 (en) 1998-09-10 1999-05-27 Method for administering a sustained release ranolanolazine formulation

Publications (1)

Publication Number Publication Date
AR022085A1 true AR022085A1 (es) 2002-09-04

Family

ID=26796494

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP990104545A AR022085A1 (es) 1998-09-10 1999-09-09 Una forma de dosificacion farmaceutica de liberacion sostenida y una tableta comprimida
ARP060100700A AR052921A1 (es) 1998-09-10 2006-02-24 Uso de ranolazina para la preparacion de una composicion farmaceutica y composicion farmaceutica
ARP060100699A AR053440A2 (es) 1998-09-10 2006-02-24 Uso de una forma de dosificacion farmaceutica de liberacion sostenida para la manufactura de un medicamento, dicha forma de dosificacion farmaceutica y una tableta comprimida

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP060100700A AR052921A1 (es) 1998-09-10 2006-02-24 Uso de ranolazina para la preparacion de una composicion farmaceutica y composicion farmaceutica
ARP060100699A AR053440A2 (es) 1998-09-10 2006-02-24 Uso de una forma de dosificacion farmaceutica de liberacion sostenida para la manufactura de un medicamento, dicha forma de dosificacion farmaceutica y una tableta comprimida

Country Status (33)

Country Link
US (14) US6303607B1 (es)
EP (3) EP1527779A1 (es)
JP (2) JP3745621B2 (es)
KR (1) KR100475759B1 (es)
CN (2) CN1193757C (es)
AR (3) AR022085A1 (es)
AT (2) ATE285774T1 (es)
AU (4) AU760435B2 (es)
BR (2) BR9913626A (es)
CA (2) CA2342390C (es)
CY (1) CY2008020I1 (es)
CZ (2) CZ301375B6 (es)
DE (3) DE122008000065I1 (es)
DK (2) DK1109558T3 (es)
ES (2) ES2234302T3 (es)
FR (1) FR09C0001I2 (es)
GE (1) GEP20053420B (es)
HK (2) HK1040060A1 (es)
HU (2) HU224215B1 (es)
IL (6) IL141893A0 (es)
LU (1) LU91504I2 (es)
MX (2) MXPA01002598A (es)
NL (1) NL300371I2 (es)
NO (4) NO319434B1 (es)
NZ (2) NZ510384A (es)
PL (3) PL196668B1 (es)
PT (2) PT1096937E (es)
RU (2) RU2214233C2 (es)
SI (2) SI1096937T1 (es)
TR (2) TR200101261T2 (es)
TW (1) TWI241911B (es)
UA (2) UA67793C2 (es)
WO (2) WO2000013686A2 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation
CA2398691A1 (en) 2000-02-18 2001-08-23 Cv Therapeutics, Inc. Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure
AU2001277938A1 (en) * 2000-07-21 2002-02-05 Cv Therapeutics, Inc. Method for treating angina
AU2001211213A1 (en) * 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US20080109040A1 (en) * 2002-04-04 2008-05-08 Luiz Belardinelli Method of treating arrhythmias
US20030220344A1 (en) * 2002-04-04 2003-11-27 Luiz Belardinelli Method of treating arrhythmias
EP1492511B3 (fr) 2002-04-09 2012-05-02 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
ATE407674T1 (de) * 2002-04-09 2008-09-15 Flamel Tech Sa Orale pharmazeutische formulierung in form einer wässrigen suspension von mikrokapseln zur modifizierten freisetzung von amoxicillin
WO2003099281A2 (en) 2002-05-21 2003-12-04 Cv Therapeutics, Inc. Administration of a partial fatty acid inhibitor such as ranolazine for the treatment of diabetes
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
TWI350762B (en) 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
GB0403098D0 (en) 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
RU2384332C2 (ru) * 2005-01-06 2010-03-20 Си Ви Терапьютикс, Инк. Фармацевтические препаративные формы замедленного высвобождения
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
EP1909767A2 (en) * 2005-07-28 2008-04-16 Supernus Pharmaceuticals, Inc. Modified release tablet formulations with enhanced mechanical properties
US20090091253A1 (en) * 2006-03-17 2009-04-09 Konica Minolta Holdings, Inc. Organic electroluminescent element, display device and lighting device
FI20060501L (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa
US20090312340A1 (en) * 2007-02-13 2009-12-17 Whedy Wang Use of ranolazine for the treatment of cardiovascular diseases
JP2010518169A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 心血管疾患の処置のためのラノラジンの使用
JP2010518171A (ja) * 2007-02-13 2010-05-27 ギリアード・パロ・アルト・インコーポレイテッド 非冠微小血管疾患の処置のためのラノラジンの使用
EP2117549A1 (en) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Use of ranolazine for the treatment of coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
JP2010520291A (ja) * 2007-03-07 2010-06-10 コンサート ファーマシューティカルズ インコーポレイテッド 抗狭心症化合物としての重水素化ピペラジン誘導体
WO2008116083A1 (en) * 2007-03-22 2008-09-25 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
US20080299195A1 (en) * 2007-05-31 2008-12-04 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
CN101066253B (zh) * 2007-06-07 2011-01-05 北京本草天源药物研究院 一种雷诺嗪缓释片
KR20100047190A (ko) * 2007-06-13 2010-05-07 오스펙스 파마슈티칼스, 인코포레이티드 치환 피페라진
US20090012103A1 (en) * 2007-07-05 2009-01-08 Matthew Abelman Substituted heterocyclic compounds
US20090076018A1 (en) * 2007-09-15 2009-03-19 Protia, Llc Deuterium-enriched ranolazine
AU2009212254A1 (en) * 2008-02-06 2009-08-13 Cv Therapeutics, Inc. Use of Ranolazine for treating pain
US20100292217A1 (en) * 2009-05-14 2010-11-18 Gilead Palo Alto, Inc. Ranolazine for the treatment of cns disorders
US8901128B2 (en) 2009-05-28 2014-12-02 Lupin Limited Pharmaceutical compositions of ranolazine
US20120177729A1 (en) * 2009-09-25 2012-07-12 Lupin Limited Sustained release composition of ranolazine
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
TW201215392A (en) 2010-06-16 2012-04-16 Gilead Sciences Inc Use of ranolazine for treating pulmonary hypertension
ES2414384T3 (es) 2011-05-11 2013-07-19 Ratiopharm Gmbh Composición de liberación modificada que comprende ranolazina
NO3175985T3 (es) 2011-07-01 2018-04-28
JP2014531454A (ja) 2011-09-21 2014-11-27 ギリアード サイエンシーズ， インコーポレイテッド グルカゴン分泌を減少させるナトリウムチャネルブロッカー
WO2014176557A2 (en) * 2013-04-26 2014-10-30 Chanrx Corporation Methods for calibrating the administration of vanoxerine for terminating acute episodes of cardiac arrhythmia, restoring normal sinus rhythm, preventing recurrence of cardiac arrhythmia and maintaining normal sinus rythm in mammals
CN104758265B (zh) * 2014-01-07 2019-05-17 四川海思科制药有限公司 一种雷诺嗪缓释片药物组合物及其制备方法
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
TW201717919A (zh) * 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
AR110252A1 (es) 2016-11-30 2019-03-13 Gilead Sciences Inc Compuestos heterocíclicos fusionados como inhibidores de la quinasa cam
US10898444B2 (en) * 2017-06-01 2021-01-26 Sun Pharmaceutical Industries Limited Extended release multiparticulates of ranolazine
CN112438955A (zh) * 2019-08-30 2021-03-05 深圳翰宇药业股份有限公司 一种雷诺嗪缓释组合物及其制备方法
AU2020408323A1 (en) 2019-12-16 2022-08-11 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HF-pEF)
CN110898024A (zh) * 2019-12-17 2020-03-24 卓和药业集团有限公司 一种治疗心绞痛的药物组合物及制备方法
GR1010345B (el) * 2021-12-16 2022-11-28 Φαρματεν Α.Β.Ε.Ε., Δισκια παρατεταμενης αποδεσμευσης που περιλαμβανουν ρανολαζινη και μεθοδος παραγωγης αυτων
GR1010510B (el) * 2022-06-07 2023-07-20 Ελπεν Α.Ε. Φαρμακευτικη Βιομηχανια, Στερεες φαρμακοτεχνικες μορφες παρατεταμενης αποδεσμευσης ρανολαζινης

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4567264A (en) 1983-05-18 1986-01-28 Syntex (U.S.A.) Inc. Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry
IL81419A0 (en) * 1986-01-30 1987-08-31 Syntex Inc Long acting sustained release pharmaceutical compositions containing dihydropyridines and their preparation
EP0719558B1 (en) * 1989-06-23 2002-06-05 Syntex (U.S.A.) LLC Ranolazine and related piperazines for use in the treatment of shock conditions
US5527545A (en) 1989-09-18 1996-06-18 Recordati S.A. Chemical And Pharmaceutical Company Liquid-suspension controlled-release pharmaceutical composition
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
JP2516524B2 (ja) * 1992-04-27 1996-07-24 大洋薬品工業株式会社 持続性製剤
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
US5455045A (en) 1993-05-13 1995-10-03 Syntex (U.S.A.) Inc. High dose formulations
JPH07112932A (ja) * 1993-08-27 1995-05-02 Mitsui Toatsu Chem Inc 徐放性医薬製剤
US5525606A (en) * 1994-08-01 1996-06-11 The United States Of America As Represented By The Department Of Health And Human Services Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines
JPH08259446A (ja) * 1995-01-24 1996-10-08 Mitsui Toatsu Chem Inc 持効性医薬製剤
JPH08310946A (ja) * 1995-05-19 1996-11-26 Yuutoku Yakuhin Kogyo Kk 経皮吸収製剤
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
US6479496B1 (en) * 1998-09-10 2002-11-12 Cv Therapeutics, Inc. Methods for treating angina with ranolazine
US6303607B1 (en) * 1998-09-10 2001-10-16 Cv Therapeutics, Inc. Method for administering a sustained release ranolanolazine formulation

Also Published As

Publication number Publication date
NO20011192L (no) 2001-04-30
US20020004506A1 (en) 2002-01-10
NZ510386A (en) 2003-08-29
KR100475759B1 (ko) 2005-03-10
US20020090396A1 (en) 2002-07-11
EP1527779A1 (en) 2005-05-04
HUP0103844A3 (en) 2002-11-28
US20040029890A1 (en) 2004-02-12
CN1193757C (zh) 2005-03-23
HUP0103844A2 (hu) 2002-04-29
WO2000013686A3 (en) 2000-07-06
WO2000013687A3 (en) 2000-06-29
TR200101262T2 (tr) 2001-12-21
US20030099705A1 (en) 2003-05-29
HK1040060A1 (en) 2002-05-24
DK1096937T3 (da) 2005-05-09
ES2177346T3 (es) 2002-12-01
EP1096937B1 (en) 2004-12-29
US6369062B1 (en) 2002-04-09
US6864258B2 (en) 2005-03-08
AR053440A2 (es) 2007-05-09
AU2008207703A1 (en) 2008-09-25
US20050153982A1 (en) 2005-07-14
FR09C0001I2 (es) 2009-12-18
HK1044284B (zh) 2005-07-15
JP2006096757A (ja) 2006-04-13
PL347073A1 (en) 2002-03-11
WO2000013686A2 (en) 2000-03-16
ATE217794T1 (de) 2002-06-15
EP1096937A2 (en) 2001-05-09
US20050059667A1 (en) 2005-03-17
US6620814B2 (en) 2003-09-16
PT1109558E (pt) 2002-10-31
CA2343376A1 (en) 2000-03-16
ES2234302T3 (es) 2005-06-16
GEP20053420B (en) 2005-01-25
BR9913626A (pt) 2001-12-04
UA67793C2 (uk) 2004-07-15
BR9913553A (pt) 2001-10-23
US6303607B1 (en) 2001-10-16
CN1211086C (zh) 2005-07-20
JP3745621B2 (ja) 2006-02-15
US20030166659A1 (en) 2003-09-04
IL141892A (en) 2006-08-20
HU224215B1 (hu) 2005-06-28
PL348249A1 (en) 2002-05-20
WO2000013687A2 (en) 2000-03-16
NO20054324L (no) 2001-04-30
CN1321088A (zh) 2001-11-07
HUP0104088A3 (en) 2002-12-28
DE122008000065I1 (de) 2009-04-09
AU6142599A (en) 2000-03-27
IL141893A0 (en) 2002-03-10
CZ301375B6 (cs) 2010-02-03
DE69922964D1 (de) 2005-02-03
CY2008020I2 (el) 2010-07-28
EP1109558A2 (en) 2001-06-27
NL300371I1 (nl) 2009-02-02
IL141893A (en) 2008-08-07
US6852724B2 (en) 2005-02-08
PT1096937E (pt) 2005-04-29
DE69922964T2 (de) 2005-12-08
NO2009005I1 (no) 2009-03-16
SI1109558T1 (en) 2002-10-31
UA75027C2 (uk) 2006-03-15
NO20011191D0 (no) 2001-03-08
US20060217397A1 (en) 2006-09-28
PL196668B1 (pl) 2008-01-31
HK1044284A1 (en) 2002-10-18
NO20011192D0 (no) 2001-03-08
IL180864A0 (en) 2007-07-04
JP2002524416A (ja) 2002-08-06
NL300371I2 (nl) 2009-10-01
NO320986B1 (no) 2006-02-20
IL141892A0 (en) 2002-03-10
TR200101261T2 (tr) 2002-05-21
MXPA01002598A (es) 2002-04-08
MXPA01002599A (es) 2005-02-17
DE69901570D1 (de) 2002-06-27
NZ510384A (en) 2002-10-25
US20030100566A1 (en) 2003-05-29
LU91504I9 (es) 2019-01-02
SI1096937T1 (en) 2005-04-30
DK1109558T3 (da) 2002-08-26
KR20010089874A (ko) 2001-10-12
US20040097514A1 (en) 2004-05-20
US6617328B2 (en) 2003-09-09
AU744071B2 (en) 2002-02-14
CA2342390A1 (en) 2000-03-16
IL175371A0 (en) 2006-09-05
ATE285774T1 (de) 2005-01-15
US6562826B1 (en) 2003-05-13
CZ2001880A3 (cs) 2001-08-15
CA2342390C (en) 2006-08-29
LU91504I2 (fr) 2009-02-03
RU2207856C2 (ru) 2003-07-10
AU6036499A (en) 2000-03-27
DE69901570T2 (de) 2003-01-09
EP1096937B9 (en) 2007-02-28
CA2343376C (en) 2007-01-09
NO2009005I2 (es) 2010-06-28
FR09C0001I1 (es) 2009-02-27
AR052921A1 (es) 2007-04-11
AU760435B2 (en) 2003-05-15
TWI241911B (en) 2005-10-21
CY2008020I1 (el) 2010-07-28
PL196263B1 (pl) 2007-12-31
NO319434B1 (no) 2005-08-15
AU2008207707A1 (en) 2008-09-25
RU2214233C2 (ru) 2003-10-20
CZ301341B6 (cs) 2010-01-20
US20060147521A1 (en) 2006-07-06
CN1354665A (zh) 2002-06-19
CZ2001879A3 (cs) 2001-08-15
US6503911B2 (en) 2003-01-07
PL202207B1 (pl) 2009-06-30
NO20011191L (no) 2001-04-30
EP1109558B1 (en) 2002-05-22
HUP0104088A2 (hu) 2002-05-29
US6525057B2 (en) 2003-02-25

Similar Documents

Publication Publication Date Title
AR022085A1 (es) Una forma de dosificacion farmaceutica de liberacion sostenida y una tableta comprimida
ES2336943T3 (es) Comprimido de bosentan dispersable.
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
EA200500891A1 (ru) Фармацевтические композиции, содержащие щелочные или соответственно кислые лекарственные соединения, поверхностно-активное вещество и физиологически приемлемую водорастворимую кислоту или соответственно основание
IS7006A (is) Tvívetnis 3-piperidínóprópíófenon og lyf sem innihalda téð efnasambönd
AR036658A1 (es) Formulacion de dosificacion oral de fundicion instantanea
KR850700212A (ko) 서방성 약제학적 캼셀제
UA85359C2 (ru) Таблетка, содержащая гранулированный материал с kmd-3213
SE9901573D0 (sv) New compounds
BR9807992A (pt) Comprimidos para engolir os quais compreendem paracetamol
AR019053A1 (es) Uso de 2'2'-difluoronucleosidos para la preparacion de un medicamento y composicion farmaceutica y producto farmaceutico que los contienen
HUP0301390A2 (hu) Valzartánt tartalmazó orális gyógyászati készítmény
RU2005122403A (ru) Композиции нестероидных противовоспалительных лекарственных средств, противозастойных средств и антигистаминов
ES2060015T3 (es) Derivados arilicos anti-inflamatorios.
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
SE8901003L (sv) Snabbloesliga preparat
ES2610469T3 (es) Nuevas formulaciones farmacéuticas útiles en el tratamiento del insomnio
AR035006A1 (es) Derivado de naftiridin-dibenzo[a,d]ciclohepteno-10-acetico, composicion farmaceutica, y el uso de dicho derivado para la fabricacion de un medicamento.
AR029637A1 (es) Compuestos de guanidina, antagonistas de los receptores de la il-8, una composicion farmaceutica que los contiene y el uso de los mismos para la manufactura de un medicamento
HUP0203148A2 (hu) Mirtazapint tartalmazó orálisan dezintegrálódó készítmény
SE9901572D0 (sv) New compounds
AR002727A1 (es) El uso de ridogrel para la fabricacion de un medicamento util para el tratamiento de enfermedades digestivas inflamatorias, una composicionfarmaceutica que comprende ridogrel y un procedimiento para preparar dicha composicion.
KR20010006835A (ko) 경구용 속붕해정
JPS5942316A (ja) 睡眠障害治療剤
EA200101108A1 (ru) Полиморфные модификации кристаллического цитрата азабицикло[2.2.2]октан-3-амина и их фармацевтические композиции

Legal Events

Date Code Title Description
FG Grant, registration